NeuroGT — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

NeuroGT is a private, preclinical-stage biotech founded in 2021 and based in Cambridge, USA, developing transformative gene therapies for rare neurogenetic disorders. The company's core strength lies in its integrated technology platform, which includes an AAV9 delivery system, an antibody-clearing technology to enable re-dosing, and novel manufacturing capabilities. Led by a founder with a strong translational track record in AAV gene therapy for MPS disorders, NeuroGT is targeting high-unmet-need pediatric conditions with the goal of providing durable, one-time treatments. The company is pre-revenue and appears to be seeking partnerships and investment to advance its pipeline.

Rare Neurogenetic DiseasesLysosomal Storage Disorders

Technology Platform

Integrated AAV9-based gene therapy platform featuring a neurotropic AAV9 vector for blood-brain barrier crossing, Antibody Cleaver (AbC) technology to enable re-dosing, AAV-mediated EV-mRNA cargo for cross-correction, and a scalable suspension cell-based manufacturing platform.

Opportunities

The high unmet need in severe pediatric neurogenetic disorders like MPS supports significant pricing and reimbursement potential for a transformative one-time therapy.

Success with its platform in MPS could enable expansion into a broader range of CNS and genetic diseases.

Strategic partnerships for co-development or licensing could provide non-dilutive funding and accelerate pipeline progress.

Risk Factors

The company faces high scientific risk in translating novel platform technologies (AbC, EV cargo) and AAV9 delivery from preclinical models to safe and effective human therapies.

As a pre-revenue, private company, it is dependent on raising substantial capital in a competitive funding environment to finance costly R&D and manufacturing build-out.

Regulatory pathways for complex gene therapies are evolving and uncertain, and the space faces competition from other biotechs developing advanced therapies for similar indications.

Competitive Landscape

NeuroGT competes in the active field of gene therapy for lysosomal storage disorders, facing competition from other biotechs and large pharma companies developing AAV-based therapies, enzyme replacement therapies, and other modalities. Its focus on enabling technologies like antibody clearance and EV-mediated cross-correction aims to differentiate its approach. The proven translational experience of its leadership in specifically targeting MPS with AAV9 provides a distinct competitive advantage in navigating development challenges.

More companies in Cell & Gene Therapy →More companies in United States →